| 
Mechanism-based peripheral blood biomarkers to evaluate anticancer effects of the plinabulin/docetaxel combination (plin/doc) vs. doc alone in second/third line EGFR wild-type (WT) NSCLC.  | 
|   | 
 | 
Employment - Piedmont Cancer Institute  | 
Stock and Other Ownership Interests  - OneOncology  | 
Consulting or Advisory Role - AstraZeneca; Janssen; Menarini; Seagen  | 
Speakers' Bureau - Sanofi; SOBI  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Employment - BeyondSpring Pharmaceuticals  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Employment - BeyondSpring Pharmaceuticals  | 
Leadership - BeyondSpring Pharmaceuticals  | 
Stock and Other Ownership Interests  - BeyondSpring Pharmaceuticals  | 
Patents, Royalties, Other Intellectual Property - BeyondSpring Pharmaceuticals  | 
|   | 
 | 
Employment - BeyondSpring Pharmaceuticals  | 
Leadership - BeyondSpring Pharmaceuticals  | 
Stock and Other Ownership Interests  - BeyondSpring Pharmaceuticals  |